Advertisement

Transplantation Tolerance

      Summary

      Tolerance following organ transplantation was first described in experimental models over 50 years ago. Reports of tolerance in clinical transplantation have appeared in the literature sporadically for decades. Despite this long-standing fascination with transplantation tolerance, the ability to reproducibly induce tolerance in humans undergoing organ transplantation has remained elusive. Recent advances in our knowledge of the mechanisms that contribute to the induction and maintenance of tolerance as well as those factors that oppose tolerance may allow the design of clinical trials aimed at introducing tolerance-inducing strategies into clinical transplantation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Billingham R.E.
        • Brent L.
        • Medawar P.B.
        “Actively acquired tolerance” of foreign cells.
        Nature. 1953; 172: 603-606
        • Owen R.D.
        Immunogeneic consequences of vascular anastomoses between bovine twins.
        Science. 1945; 102: 400-401
        • Owens M.L.
        • Maxwell J.G.
        • Goodnight J.
        • Wolcott M.W.
        Discontinuance of immunosuppression in renal transplant patients.
        Arch Surg. 1975; 110: 1450-1451
        • Uehling D.T.
        • Hussey J.L.
        • Weinstein A.B.
        • Wank R.
        • Bach F.H.
        Cessation of immunosuppression after renal transplantation.
        Surgery. 1976; 79: 278-282
        • Main J.M.
        • Prehn R.T.
        Successful skin homografts after the administration of high dosage X radiation and homologous bon marrow.
        J Natl Cancer Inst. 1955; 15: 1023-1028
        • Ildstad S.T.
        • Sachs D.H.
        Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts.
        Nature. 1984; 307: 168-170
        • Clarkson M.R.
        • Sayegh M.H.
        T-cell costimulatory pathways in allograft rejection and tolerance.
        Transplantation. 2005; 80: 555-563
        • Lenschow D.J.
        • Zeng Y.
        • Thistlethwaite J.R.
        • Montag A.
        • Brady W.
        • Gibson M.G.
        • et al.
        Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg.
        Science. 1992; 257: 789-792
        • Turka L.A.
        • Linsley P.S.
        • Lin H.
        • Brady W.
        • Leiden J.M.
        • Wei R.Q.
        • et al.
        T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.
        Proc Natl Acad Sci U S A. 1992; 89: 11102-11105
        • Larsen C.P.
        • Elwood E.T.
        • Alexander D.Z.
        • Ritchie S.C.
        • Hendrix R.
        • Tucker-Burden C.
        • et al.
        Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.
        Nature. 1996; 381: 434-438
        • Kirk A.D.
        • Harlan D.M.
        • Armstrong N.N.
        • Davis T.A.
        • Dong Y.
        • Gray G.S.
        • et al.
        CTLA4Ig and anti-CD40 ligand prevent renal allograft rejection in primates.
        Proc Natl Acad Sci U S A. 1997; 94: 8789-8794
        • Adams A.B.
        • Shirasugi N.
        • Jones T.R.
        • Durham M.M.
        • Strobert E.A.
        • Cowan S.
        • et al.
        Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival.
        J Immunol. 2005; 174: 542-550
        • Kirk A.D.
        • Tadaki D.K.
        • Celniker A.
        • Batty D.S.
        • Berning J.D.
        • Colonna J.O.
        • et al.
        Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates.
        Transplantation. 2001; 72: 377-384
        • Larsen C.P.
        • Pearson T.C.
        • Adams A.B.
        • Tso P.
        • Shirasugi N.
        • Strobertm E.
        • et al.
        Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.
        Am J Transplant. 2005; 5: 443-453
        • Kawai T.
        • Sogawa H.
        • Boskovic S.
        • Abrahamian G.
        • Smith R.N.
        • Wee S.L.
        • et al.
        CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates.
        Am J Transplant. 2004; 4: 1391-1398
        • Kawai T.
        • Cosimi A.B.
        • Wee S.L.
        • Houser S.
        • Andrews D.
        • Sogawa H.
        • et al.
        Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys.
        Transplantation. 2002; 73: 1757-1764
        • Knechtle S.J.
        • Vargo D.
        • Fechner J.
        • Zhai Y.
        • Wang J.
        • Hanaway M.J.
        • et al.
        FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts.
        Transplantation. 1997; 63: 1-6
        • Torrealba J.R.
        • Fernandez L.A.
        • Kanmaz T.
        • Oberley T.D.
        • Schultz J.M.
        • Brunner K.G.
        • et al.
        Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection.
        Transplantation. 2003; 76: 524-530
        • Torrealba J.R.
        • Katayama M.
        • Fechner Jr, J.H.
        • Jankowska-Gan E.
        • Kusaka S.
        • Xu Q.
        • et al.
        Metastable tolerance to rhesus monkey renal transplants is correlated with allograft TGF-beta 1+CD4+ T regulatory cell infiltrates.
        J Immunol. 2004; 172: 5753-5764
        • Bashuda H.
        • Kimikawa M.
        • Seino K.
        • Kato Y.
        • Ono F.
        • Shimizu A.
        • et al.
        Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates.
        J Clin Invest. 2005; 115: 1896-1902
        • Mazariegos G.V.
        • Reyes J.
        • Marino I.R.
        • Demetris A.J.
        • Flynn B.
        • Irish W.
        • et al.
        Weaning of immunosuppression in liver transplant recipients.
        Transplantation. 1997; 63: 243-249
        • Roussey-Kesler G.
        • Giral M.
        • Moreau A.
        • Subra J.F.
        • Legendre C.
        • Noel C.
        • et al.
        Clinical operational tolerance after kidney transplantation.
        Am J Transplant. 2006; 6: 736-746
        • Louis S.
        • Braudeau C.
        • Giral M.
        • Dupont A.
        • Moizant F.
        • Robillard N.
        • et al.
        Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance.
        Transplantation. 2006; 81: 398-407
        • Baeten D.
        • Louis S.
        • Braud C.
        • Braudeau C.
        • Ballet C.
        • Moizant F.
        • et al.
        Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients.
        J Am Soc Nephrol. 2006; 17: 294-304
        • Ballet C.
        • Roussey-Kesler G.
        • Aubin J.T.
        • Brouard S.
        • Giral M.
        • Miqueu P.
        • et al.
        Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft.
        Am J Transplant. 2006; 6: 2796-2801
        • Kirk A.D.
        • Hale D.A.
        • Cendales L.K.
        • Hoffmann S.C.
        • Kampen R.L.
        • Kleiner D.E.
        • et al.
        Results from a human tolerance trial using alemtuzumab (Campath-1H) with deoxyspergualin (DSG).
        Am J Transplant. 2003; 3: S310
        • Pearl J.P.
        • McCoy K.L.
        • Wakefield T.
        • Swanson S.J.
        • Hale D.A.
        • Mannon R.B.
        • et al.
        Repopulating cells after aggressive lymphocyte depletion are predominantly memory phenotype.
        Am J Transplant. 2003; 3: S446
        • Kirk A.D.
        • Mannon R.B.
        • Kleiner D.E.
        • Swanson J.S.
        • Kampen R.L.
        • Cendales L.K.
        • et al.
        Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin.
        Transplantation. 2005; 80: 1051-1059
        • Barth R.N.
        • Janus C.A.
        • Lillesand C.A.
        • Radke N.A.
        • Pirsch J.D.
        • Becker B.N.
        • et al.
        Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.
        Transpl Int. 2006; 19: 885-892
        • Tan H.P.
        • Kaczorowski D.J.
        • Basu A.
        • Unruh M.
        • McCauley J.
        • Wu C.
        • et al.
        Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.
        Am J Transplant. 2006; 6: 2409-2417
        • Fudaba Y.
        • Spitzer T.R.
        • Shaffer J.
        • Kawai T.
        • Fehr T.
        • Delmonico F.
        • et al.
        Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses.
        Am J Transplant. 2006; 6: 2121-2133
        • Kawai T.
        • Sachs D.H.
        • Spitzer T.R.
        • Tolkoff-Rubin N.
        • Delmonico F.L.
        • Saidman S.L.
        • et al.
        Combined kidney and bone marrow transplantation for induction of mixed chimerism and renal allograft tolerance in HLA matched and mismatched recipients.
        Am J Transplant. 2005; 5: 1535
        • Suchin E.J.
        • Langmuir P.B.
        • Palmer E.
        • Sayegh M.H.
        • Wells A.D.
        • Turka L.A.
        Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question.
        J Immunol. 2001; 166: 973-981
        • Wu Z.
        • Bensinger S.J.
        • Zhang J.
        • Chen C.
        • Yuan X.
        • Huang X.
        • et al.
        Homeostatic proliferation is a barrier to transplantation tolerance.
        Nat Med. 2004; 10: 87-92
        • Valujskikh A.
        The challenge of inhibiting alloreactive T-cell memory.
        Am J Transplant. 2006; 6: 647-651
        • Adams A.B.
        • Pearson T.C.
        • Larsen C.P.
        Heterologous immunity: an overlooked barrier to tolerance.
        Immunol Rev. 2003; 196: 147-160
        • Walker W.E.
        • Nasr I.W.
        • Camirand G.
        • Tesar B.M.
        • Booth C.J.
        • Goldstein D.R.
        Absence of innate MyD88 signaling promotes inducible allograft acceptance.
        J Immunol. 2006; 177: 5307-5316
        • Chen L.
        • Wang T.
        • Zhou P.
        • Ma L.
        • Yin D.
        • Shen J.
        • et al.
        TLR engagement prevents transplantation tolerance.
        Am J Transplant. 2006; 6: 2282-2291
        • Lakkis F.G.
        • Arakelov A.
        • Konieczny B.T.
        • Inoue Y.
        Immunologic ‘ignorance’ of vascularized organ transplants in the absence of secondary lymphoid tissue.
        Nat Med. 2000; 6: 686-688
        • Salama A.D.
        • Najafian N.
        • Clarkson M.R.
        • Harmon W.E.
        • Sayegh M.H.
        Regulatory CD25+ T cells in human kidney transplant recipients.
        J Am Soc Nephrol. 2003; 14: 1643-1651
        • VanBuskirk A.M.
        • Burlingham W.J.
        • Jankowska-Gan E.
        • Chin T.
        • Kusaka S.
        • Geissler F.
        • et al.
        Human allograft acceptance is associated with immune regulation.
        J Clin Invest. 2000; 106: 145-155
        • Newell K.A.
        • Larsen C.P.
        Tolerance assays: measuring the unknown.
        Transplantation. 2006; 81: 1503-1509
        • Najafian N.
        • Albin M.J.
        • Newell K.A.
        How can we measure immunologic tolerance in humans?.
        J Am Soc Nephrol. 2006; 17: 2652-2663